<?xml version="1.0" encoding="UTF-8"?>
<p>In Bartolucci's study that aimed to evaluate the safety and efficacy of the infusion of umbilical cord-derived mesenchymal stem cells (UC-MSC) in patients with chronic stable HFrEF, it was concluded that improvements in left ventricular function, functional status and quality of life in patients with HFrEF were observed in those treated with (UC-MSC) in comparison with placebo. The results of this study are different from our study, and the reason for this is the type of stem cell used in the treatment of patients. As mentioned, in Bartolucci's study, the type of stem cell used originated in the umbilical cord and our study, it originated in the bone marrow [
 <xref rid="R25" ref-type="bibr">25</xref>].
</p>
